Neogenomics (NEO) Cost of Revenue (2010 - 2026)

Neogenomics (NEO) has 17 years of Cost of Revenue data on file, last reported at $109.8 million in Q2 2026.

• Quarterly Cost of Revenue rose 5.48% year-over-year to $109.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $429.8 million (up 11.18% YoY) and the FY2025 annual result came in at $413.0 million, up 11.49% from the prior year.
• Cost of Revenue climbed to $109.8 million in Q2 2026, from $105.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $109.8 million in Q2 2026 to a low of $78.9 million in Q1 2022.
• A 5-year average of $92.7 million and a median of $91.4 million in 2024 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 18.03% in 2022, down 1.75% in 2022.
• Tracing NEO's Cost of Revenue over 5 years: stood at $81.9 million in 2022, then climbed by 7.43% to $88.0 million in 2023, then increased by 7.71% to $94.7 million in 2024, then grew by 12.75% to $106.8 million in 2025, then gained by 2.76% to $109.8 million in 2026.
• The last three Cost of Revenue figures came in at $109.8 million (Q2 2026), $105.8 million (Q1 2026), and $106.8 million (Q4 2025), per Business Quant data.